Jichuan Pharmaceuticals' Robeka hydrochloride was approved for drug registration for injections

The robekain hydrochloric acid (Nale product) was developed by AstraZeneca and was approved by the FDA in September 1996, with the domestic approval for the market in March 2005hydrochloric acid rojacaine is a aminoamide-type drug that may block the production and conduction of nerve impulses by increasing the threshold of nerve electrical stimulation, slowing the spread of nerve impulses and reducing the rising rate of the action potentialindications: surgical anesthesia: epidural anesthesia, including caesarean section; subcavity anesthesia of the cobwebs; regional blockingAcute pain control: continuous epidural infusion or intermittent single medication, such as postoperative or vaginal delivery analgesic; The first application for registration of the drug was submitted on 14 December 2011so far, the drug's cumulative research and development expenditure totals about 3.8 million yuan (unaudited)The current approval stage of the drug is approved for productionthe registration of this product is classified as the original chemical product 6 categoriesAccording to the relevant provisions of the document of the State Drug Administration's "Announcement on Matters Related to the Conformity Evaluation of The Quality and Efficacy of Generic Drugs" (No100 of 2017), the conformity evaluation of the quality and efficacy of generic drugs should still be completed after listingso far, the hydrochloric acid rolyika in the injection of domestic approval 11 pieces (including Jichuan limited), import approval 1 pieceAccording to the data of Minet, in 2018 the total sales of local anaesthetic in public hospitals in cities nationwide amounted to about 1,786 million yuan, of which the hydrochloric acid robekain injection ranked first with sales of 490 million yuan.